HC Wainwright Brokers Lower Earnings Estimates for STOK

Stoke Therapeutics, Inc. (NASDAQ:STOK) – HC Wainwright dropped their Q2 2025 earnings estimates for Stoke Therapeutics in a research note issued to investors on Wednesday, May 14th. HC Wainwright analyst A. Fein now anticipates that the company will post earnings of ($0.68) per share for the quarter, down from their prior estimate of ($0.54). HC Wainwright has a “Buy” rating and a $35.00 price objective on the stock. The consensus estimate for Stoke Therapeutics’ current full-year earnings is ($2.01) per share. HC Wainwright also issued estimates for Stoke Therapeutics’ Q3 2025 earnings at ($0.69) EPS, Q4 2025 earnings at ($0.71) EPS, FY2025 earnings at ($0.25) EPS, FY2026 earnings at ($3.48) EPS, FY2027 earnings at ($2.45) EPS and FY2028 earnings at ($1.41) EPS.

A number of other research firms have also commented on STOK. Needham & Company LLC reaffirmed a “buy” rating and set a $22.00 price objective on shares of Stoke Therapeutics in a research note on Wednesday, April 9th. Chardan Capital restated a “buy” rating and issued a $24.00 target price on shares of Stoke Therapeutics in a report on Wednesday, March 19th. Finally, Cantor Fitzgerald upgraded shares of Stoke Therapeutics to a “strong-buy” rating in a report on Wednesday. Five analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $23.20.

Stoke Therapeutics Stock Performance

Stoke Therapeutics stock opened at $9.63 on Friday. Stoke Therapeutics has a fifty-two week low of $5.35 and a fifty-two week high of $17.58. The company has a market capitalization of $525.77 million, a price-to-earnings ratio of -4.59 and a beta of 1.20. The stock has a fifty day moving average of $8.12 and a two-hundred day moving average of $9.99.

Stoke Therapeutics (NASDAQ:STOK) last issued its quarterly earnings data on Monday, March 24th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.56) by $0.38. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%. The firm had revenue of $22.61 million during the quarter, compared to the consensus estimate of $4.20 million.

Insider Activity at Stoke Therapeutics

In other Stoke Therapeutics news, insider Barry Ticho sold 3,884 shares of Stoke Therapeutics stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total value of $33,674.28. Following the completion of the sale, the insider now owns 63,962 shares in the company, valued at $554,550.54. The trade was a 5.72% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Edward M. Md Kaye sold 10,382 shares of the stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total transaction of $90,011.94. Following the transaction, the director now owns 148,253 shares in the company, valued at approximately $1,285,353.51. The trade was a 6.54% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 16,532 shares of company stock worth $143,332. 11.30% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Stoke Therapeutics

A number of hedge funds have recently made changes to their positions in the stock. ADAR1 Capital Management LLC acquired a new stake in shares of Stoke Therapeutics during the 1st quarter worth $200,000. MPM Bioimpact LLC raised its holdings in shares of Stoke Therapeutics by 1.2% in the 1st quarter. MPM Bioimpact LLC now owns 693,988 shares of the company’s stock worth $4,615,000 after purchasing an additional 8,162 shares during the period. DAFNA Capital Management LLC raised its holdings in Stoke Therapeutics by 159.5% in the first quarter. DAFNA Capital Management LLC now owns 443,998 shares of the company’s stock valued at $2,953,000 after buying an additional 272,901 shares during the period. Siren L.L.C. lifted its position in Stoke Therapeutics by 12.4% during the first quarter. Siren L.L.C. now owns 2,247,347 shares of the company’s stock valued at $14,945,000 after buying an additional 247,347 shares in the last quarter. Finally, AlphaQuest LLC purchased a new stake in Stoke Therapeutics during the first quarter worth approximately $72,000.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.